Evaluation of FID 114657 in Sjogren's Syndrome Subjects
Primary Purpose
Sjogren's Syndrome
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
FID 114657 (ORB Preserved Ocular Emulsion)
Sponsored by

About this trial
This is an interventional treatment trial for Sjogren's Syndrome focused on measuring Sjogren's Syndrome, Dry Eye
Eligibility Criteria
Inclusion Criteria:
- Patients must be at least 18 years of age, must read and sign the informed consent form (ICF), and must agree to comply with the study requirements.
- Patients must have a best corrected visual acuity of 0.6 LogMar or better in each eye, must report having an ocular examination in the last two years and must be using topical ocular dry eye therapy (artificial tears or Restasis) at least 4 times per day.
- Patients must have been diagnosed with Sjogren's Syndrome (confirmed or consistent with the American-European Consensus Criteria 2002).
Exclusion Criteria:
- Patients cannot wear contact lenses within one week prior to visit 1 and cannot wear their contact lenses during the study.
- Patients cannot have a history of hypersensitivity to any component of FID 114657, and cannot have diabetes (Type 1 or 2).
- Patients cannot have ocular or intraocular surgery or serious ocular trauma within the past 6 months, and cannot have an eyelid abnormality that might affect lid function.
- Patients cannot have punctal plugs that were placed less than or equal to 30 days prior to Visit 1, and cannot have active infections or inflammations not associated with Sjogren's Syndrome.
- They cannot have started or changed the dose of chronic systemic medication within 7 days prior to visit 1, and must remain on a stable dosing regimen for the duration of the study.
- Patients cannot have participated in another investigational clinical or research study within 30 days of visit 1 and are not allowed to participate in any other drug or device clinical trial for the duration of this study.
- Patients cannot have any findings in the vitreous, retina, macula and choroid that show signs of active inflammation and/or any structural change that in the opinion of the investigator is considered abnormal or unstable for that participant and/or a score of greater than 0 for the optic nerve.
- Patients can not have had punctal cauterization within 30 days prior to Visit 1, have a history of undergoing prior cataract surgery with complications as a result of the cataract surgery.
- Participants who have undergone prior cataract surgery without complications must be at least six months post-op with a stable refractive error.
- Patients cannot have received ocular prescription therapy in the last 30 days (Restasis can be used as long as stable for at least 30 days).
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
FID 114657 (ORB Preserved Ocular Emulsion)
Arm Description
ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
Outcomes
Primary Outcome Measures
Preference based on subject's relief of dry eye
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01079871
Brief Title
Evaluation of FID 114657 in Sjogren's Syndrome Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to assess the overall Sjogren's Syndrome subject's preference for a particular product. Dry eye symptom relief will also be evaluated based on clinical evaluation and a set of subject questionnaires.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sjogren's Syndrome
Keywords
Sjogren's Syndrome, Dry Eye
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
FID 114657 (ORB Preserved Ocular Emulsion)
Arm Type
Experimental
Arm Description
ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
Intervention Type
Other
Intervention Name(s)
FID 114657 (ORB Preserved Ocular Emulsion)
Intervention Description
Patients will dose as needed throughout the day (PRN) for 4 weeks.
Primary Outcome Measure Information:
Title
Preference based on subject's relief of dry eye
Time Frame
5 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients must be at least 18 years of age, must read and sign the informed consent form (ICF), and must agree to comply with the study requirements.
Patients must have a best corrected visual acuity of 0.6 LogMar or better in each eye, must report having an ocular examination in the last two years and must be using topical ocular dry eye therapy (artificial tears or Restasis) at least 4 times per day.
Patients must have been diagnosed with Sjogren's Syndrome (confirmed or consistent with the American-European Consensus Criteria 2002).
Exclusion Criteria:
Patients cannot wear contact lenses within one week prior to visit 1 and cannot wear their contact lenses during the study.
Patients cannot have a history of hypersensitivity to any component of FID 114657, and cannot have diabetes (Type 1 or 2).
Patients cannot have ocular or intraocular surgery or serious ocular trauma within the past 6 months, and cannot have an eyelid abnormality that might affect lid function.
Patients cannot have punctal plugs that were placed less than or equal to 30 days prior to Visit 1, and cannot have active infections or inflammations not associated with Sjogren's Syndrome.
They cannot have started or changed the dose of chronic systemic medication within 7 days prior to visit 1, and must remain on a stable dosing regimen for the duration of the study.
Patients cannot have participated in another investigational clinical or research study within 30 days of visit 1 and are not allowed to participate in any other drug or device clinical trial for the duration of this study.
Patients cannot have any findings in the vitreous, retina, macula and choroid that show signs of active inflammation and/or any structural change that in the opinion of the investigator is considered abnormal or unstable for that participant and/or a score of greater than 0 for the optic nerve.
Patients can not have had punctal cauterization within 30 days prior to Visit 1, have a history of undergoing prior cataract surgery with complications as a result of the cataract surgery.
Participants who have undergone prior cataract surgery without complications must be at least six months post-op with a stable refractive error.
Patients cannot have received ocular prescription therapy in the last 30 days (Restasis can be used as long as stable for at least 30 days).
12. IPD Sharing Statement
Learn more about this trial
Evaluation of FID 114657 in Sjogren's Syndrome Subjects
We'll reach out to this number within 24 hrs